|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||32.46 - 33.91|
|52 Week Range||29.22 - 108.23|
|Beta (3Y Monthly)||3.57|
|PE Ratio (TTM)||8.86|
|Earnings Date||May 8, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.18|
SAN FRANCISCO , March 6, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that its Chief Scientific Officer, Jonathan Zalevsky , Ph.D., is scheduled to present at the Cowen and Company ...
NEW YORK, March 05, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold NKTR had net inflows of $7.01 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic.
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. Nektar Therapeutics Inc had annual average EBITDA growth of 1.30% over the past ten years. Warning! GuruFocus has detected 3 Warning Signs with NKTR.
SAN FRANCISCO , March 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced early results from the ongoing dose-escalation stage of the first-in-human REVEAL Phase 1/2 clinical study ...
Shares of Tesla fell 7.84 percent after the company's underwhelming announcement that it will be launching its standard Model 3. Barclays analyst Brian Johnson even called it the " un-iPhone moment ." The electric car maker also announced store closures and layoffs in an effort to reduce costs, in addition to stating that the company will not turn a profit during its first quarter. Nektar Therapeutics NKTR — The biopharmaceutical fell nearly 6 percent Friday after reporting fourth-quarter earnings.
Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.
SAN FRANCISCO , Feb. 28, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2018 . Cash and investments in ...
NEW YORK, NY / ACCESSWIRE / February 28, 2019 / Nektar Therapeutics (NASDAQ: NKTR ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 28, 2019 at 5:00 ...
SAN FRANCISCO , Feb. 27, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced several preclinical data presentations for its immuno-oncology pipeline candidates, bempegaldesleukin* (NKTR-214), ...
The stock has risen 8.1% since the company last reported earnings on Nov. 7. Quarterly estimates have fallen 1.2 cent a share in the past month. Jim Cramer and the AAP team are watching the pharmaceuticals sector.
Goldman Sachs argues that equity investors should pay more attention to company-specific fundamentals than macro trends going forward.
SAN FRANCISCO , Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, ...
Nektar Therapeutics (NKTR) will report fourth-quarter results on Feb 28. Investors are expected to focus on pipeline progress.
SAN FRANCISCO , Feb. 21, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2018 , on Thursday, February 28, ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Small-caps and large-caps are wildly popular among investors; however, mid-capRead More...
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Nektar Therapeutics. Nektar develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States.
Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study. Of the 27 patients with urothelial cancer, 19 percent showed complete response after being treated with the combo therapy using Nektar's NKTR-214, according to data, which was presented at the Genitourinary Cancers Symposium in San Francisco. The disease, which can infect any part of the urinary tract including the renal pelvis and the bladder, is the sixth most common type of cancer in the United States, the company said.